These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 32282224)
21. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399 [No Abstract] [Full Text] [Related]
22. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections. Speth RC Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146 [No Abstract] [Full Text] [Related]
23. Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19. Wu C; Ye D; Mullick AE; Li Z; Danser AHJ; Daugherty A; Lu HS Hypertension; 2020 Oct; 76(4):e29-e30. PubMed ID: 32673509 [No Abstract] [Full Text] [Related]
24. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Zolk O; Hafner S; Schmidt CQ; Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1131-1135. PubMed ID: 32415494 [TBL] [Abstract][Full Text] [Related]
25. The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor? Sever P; Johnston SL J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320926911. PubMed ID: 32403977 [No Abstract] [Full Text] [Related]
26. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070 [No Abstract] [Full Text] [Related]
27. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic. Augoustides JGT J Cardiothorac Vasc Anesth; 2020 Jul; 34(7):1717-1719. PubMed ID: 32360010 [No Abstract] [Full Text] [Related]
28. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19? Henry RA CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254 [No Abstract] [Full Text] [Related]
29. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19. Kalra A; Hawkins ES; Nowacki AS; Jain V; Milinovich A; Saef J; Thomas G; Gebreselassie SK; Karnik SS; Jehi L; Young JB; Svensson LG; Chung MK; Mehta N Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e007115. PubMed ID: 32856462 [No Abstract] [Full Text] [Related]
30. COVID-19: The heart of the issue. Woodward B; Kermali M J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802 [No Abstract] [Full Text] [Related]
31. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019). Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular disease and the impact of COVID-19. Yoganathan A; Sajjad MS; Harky A J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799 [No Abstract] [Full Text] [Related]
33. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19. Tsioufis C; Dimitriadis K; Tousoulis D Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334 [No Abstract] [Full Text] [Related]
34. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Gersh FL Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456 [No Abstract] [Full Text] [Related]
35. COVID-19, Angiotensin Receptor Blockers, and the Brain. Saavedra JM Cell Mol Neurobiol; 2020 Jul; 40(5):667-674. PubMed ID: 32385549 [No Abstract] [Full Text] [Related]
37. Obesity and COVID-19. Azzolino D; Cesari M Front Endocrinol (Lausanne); 2020; 11():581356. PubMed ID: 33101213 [No Abstract] [Full Text] [Related]
38. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. Iaccarino G; Borghi C; Cicero AFG; Ferri C; Minuz P; Muiesan ML; Mulatero P; Mulè G; Pucci G; Salvetti M; Savoia C; Sechi LA; Volpe M; Grassi G High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):105-108. PubMed ID: 32266708 [TBL] [Abstract][Full Text] [Related]
40. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy. Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]